Ganciclovir

Kathryn Dzintars, Pharm.D. BCPS, Paul A. Pham, Pharm.D., Alice Jenh Hsu, Pharm.D.

INDICATIONS

FDA

Systemic

  • Treatment of CMV retinitis (IV) in immunocompromised patients.
  • Prophylaxis and prevention of CMV disease recurrence in pts with AIDS and solid organ transplant recipients
    • Treatment and prevention of CMV disease in immunocompromised patients; oral valganciclovir is preferred whenever oral therapy is feasible.
    • Use for primary prophylaxis in HIV is FDA approved but not currently recommended; valganciclovir is preferred.

Topical

  • Herpes keratitis (ophthalmic gel)

NON-FDA APPROVED USES

  • Castleman’s disease (limited data)

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.